Explore
Validate
Learn
Flow cytometryAntibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations
- Flow cytometry [2]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 12-9927-42 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD253 (TRAIL) Monoclonal Antibody (RIK-2), PE, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The RIK-2 monoclonal antibody reacts with human TNF-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily. TRAIL is not expressed by resting human cells but has been shown to be induced under certain activation conditions. Iin addition it is expressed on several human tumor lines. Interaction of TRAIL with its ligand, Apo-2, induces apoptosis. RIK-2 blocks TRAIL-induced apoptosis.
- Conjugate
- Yellow dye
- Antibody clone number
- RIK-2
- Concentration
- 5 µL/Test
Submitted references Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome.
Inability of plasmacytoid dendritic cells to directly lyse HIV-infected autologous CD4+ T cells despite induction of tumor necrosis factor-related apoptosis-inducing ligand.
TRAIL death receptor-4, decoy receptor-1 and decoy receptor-2 expression on CD8+ T cells correlate with the disease severity in patients with rheumatoid arthritis.
Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells.
TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages.
Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells.
Chaput N, Flament C, Locher C, Desbois M, Rey A, Rusakiewicz S, Poirier-Colame V, Pautier P, Le Cesne A, Soria JC, Paci A, Rosenzwajg M, Klatzmann D, Eggermont A, Robert C, Zitvogel L
Oncoimmunology 2013 Feb 1;2(2):e23080
Oncoimmunology 2013 Feb 1;2(2):e23080
Inability of plasmacytoid dendritic cells to directly lyse HIV-infected autologous CD4+ T cells despite induction of tumor necrosis factor-related apoptosis-inducing ligand.
Chehimi J, Papasavvas E, Tomescu C, Gekonge B, Abdulhaqq S, Raymond A, Hancock A, Vinekar K, Carty C, Reynolds G, Pistilli M, Mounzer K, Kostman J, Montaner LJ
Journal of virology 2010 Mar;84(6):2762-73
Journal of virology 2010 Mar;84(6):2762-73
TRAIL death receptor-4, decoy receptor-1 and decoy receptor-2 expression on CD8+ T cells correlate with the disease severity in patients with rheumatoid arthritis.
Bisgin A, Terzioglu E, Aydin C, Yoldas B, Yazisiz V, Balci N, Bagci H, Gorczynski RM, Akdis CA, Sanlioglu S
BMC musculoskeletal disorders 2010 Aug 27;11:192
BMC musculoskeletal disorders 2010 Aug 27;11:192
Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells.
Herbeuval JP, Hardy AW, Boasso A, Anderson SA, Dolan MJ, Dy M, Shearer GM
Proceedings of the National Academy of Sciences of the United States of America 2005 Sep 27;102(39):13974-9
Proceedings of the National Academy of Sciences of the United States of America 2005 Sep 27;102(39):13974-9
TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages.
Kaplan MJ, Ray D, Mo RR, Yung RL, Richardson BC
Journal of immunology (Baltimore, Md. : 1950) 2000 Mar 15;164(6):2897-904
Journal of immunology (Baltimore, Md. : 1950) 2000 Mar 15;164(6):2897-904
Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells.
Kayagaki N, Yamaguchi N, Nakayama M, Takeda K, Akiba H, Tsutsui H, Okamura H, Nakanishi K, Okumura K, Yagita H
Journal of immunology (Baltimore, Md. : 1950) 1999 Aug 15;163(4):1906-13
Journal of immunology (Baltimore, Md. : 1950) 1999 Aug 15;163(4):1906-13
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of non-transfected (left) and human TRAIL transfected 2PK3 cells (right) with staining buffer (autofluorescence) (open histogram) or Anti-Human CD253 (TRAIL) PE (filled histogram). Total viable cells were used for analysis.
- Conjugate
- Yellow dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- hTrail/2PK3 cells were stained with Mouse IgG1 kappa Isotype Control, PE (Product # 12-4714-82) (blue histogram) or CD253 Monoclonal Antibody, PE (purple histogram). Viable cells were used for analysis, as determined by 7-AAD (Product # 00-6993-50).
- Conjugate
- Yellow dye
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 TRAIL and its receptor (both death and decoy) expression profile on CD4 + T cells . A scattered dot plot profile of TRAIL and its receptors is provided in Panel A . Solid circles indicate RA patients while dots represent control individuals. Error bars display mean (+-) SEM. Representative flow cytometric analyses of a control individual (upper panels) and an RA patient (lower panels) are shown in Panel B , while Panel C shows the relative increase in TRAIL and its receptors on CD4 + T cells of RA patients compared to controls.
- Conjugate
- Yellow dye
